Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial) by unknown
STUDY PROTOCOL Open Access
Midodrine as adjunctive support for
treatment of refractory hypotension in the
intensive care unit: a multicenter,
randomized, placebo controlled trial (the
MIDAS trial)
Matthew H. Anstey1,2, Bradley Wibrow1,2, Tharusan Thevathasan3, Brigit Roberts1, Khushi Chhangani3,
Pauline Yeung Ng3, Alexander Levine4, Alan DiBiasio5, Todd Sarge6 and Matthias Eikermann3,7*
Abstract
Background: Patients admitted to intensive care units (ICU) are often treated with intravenous (IV) vasopressors.
Persistent hypotension and dependence on IV vasopressors in otherwise resuscitated patients lead to delay in
discharge from ICU. Midodrine is an oral alpha-1 adrenergic agonist approved for treatment of symptomatic orthostatic
hypotension. This trial aims to evaluate whether oral administration of midodrine is an effective adjunct to standard
therapy to reduce the duration of IV vasopressor treatment, and allow earlier discharge from ICU and hospital.
Methods: The MIDAS trial is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial
being conducted in the USA and Australia. We are targeting 120 patients. Adult patients admitted to the ICU who are
resuscitated and otherwise stable on low dose IV vasopressors for at least 24 h will be considered for recruitment.
Participants will be randomized to receive midodrine (20 mg) or placebo three times a day, in addition to standard
care. The primary outcome is time (hours) from initiation of midodrine or placebo to discontinuation of IV vasopressors.
Secondary outcomes include time (hours) from ICU admission to discharge readiness, ICU length of stay (LOS) (days),
hospital LOS (days), rates of ICU readmission, and rates of adverse events related to midodrine administration.
Discussion: Midodrine is approved by the Food and Drug Administration (FDA) for the treatment of symptomatic
orthostatic hypotension. In August 2010, FDA proposed to withdraw approval of midodrine because of lack of studies
that verify the clinical benefit of the drug. We obtained Investigational New Drug (IND 113,330) approval to study its
effects in critically ill patients who require IV vasopressors but are otherwise ready for discharge from the ICU. A pilot
observational study in a cohort of surgical ICU patients showed that the rate of decline in vasopressor requirements
increased after initiation of midodrine treatment. We hypothesize that midodrine administration is effective to wean IV
vasopressors and shorten ICU and hospital LOS. This trial may have significant implications on lowering costs of
hospital care and obtaining FDA approval for new indications for midodrine.
Trial Registration: This study has been registered at clinicaltrials.gov on 02/09/2012 (NCT01531959).
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Background
Treatment with vasopressors is one of the most common
reasons for admission to an intensive care unit (ICU) [1].
Persistent hypotension in otherwise resuscitated patients
can be a delay to discharging patients from the ICU. The
addition of oral midodrine may be a solution to reduce
the duration of time the patient remains on IV vasopres-
sors and ICU length of stay (LOS).
Midodrine, an oral alpha-1 adrenergic agonist, has ap-
proval by the United States Federal Drug Administration
(FDA) for the treatmentof symptomatic orthostatic
hypotension [2]. Midodrine is a prodrug that is metabo-
lized to form desglymidodrine, with peak blood levels of
midodrine reached within 30 min and the active metabol-
ite peaking about 1 to 2 h after administration [3]. It has a
relatively safe side effect profile with minimal central ner-
vous system side effects, and good oral bioavailability [4].
Midodrine has previously been evaluated in a series of
prospective trials for orthostatic hypotension. Jankovic et al.
found a dose of 10 mg three times daily (TDS) increased
standing systolic blood pressure by 22 mmHg versus pla-
cebo [5]. Wright et al. conducted a dose response study
and found that midodrine (10 mg and 20 mg) increased
standing blood pressure compared with placebo [3].
Midodrine has also been studied in the setting of
dialysis-induced hypotension, and administration of 2.5-
10 mg prior to dialysis improved the symptoms of intra-
dialytic hypotension and increased post-dialysis systolic
blood pressure [6].
In the critical care environment, the authors have ob-
tained an Investigational New Drug (IND) approval from
the United States FDA (IND 113,330; date of receipt:
September 12, 2011) to study its effects in patients who
require low dose IV vasopressors following resuscitation.
We then conducted an observational study on the use of
oral midodrine to hasten weaning of IV vasopressors in a
cohort of surgical ICU patients [7]. In this prospective
observational study, 20 patients who met surgical ICU
discharge criteria except for persistent requirement for IV
vasopressors (phenylephrine <150 mcg/min or noradren-
aline <8 mcg/min) received oral midodrine (modal dose
20 mg, range 5–20 mg) TDS. Requirements for IV vaso-
pressors were assessed following each of the first four doses
of midodrine. The rates of decline of vasopressor require-
ment in the 12 h preceding midodrine, and from initiation
of midodrine until 4 h post the fourth dose were calculated.
6 of 20 study patients were able to be weaned from vaso-
pressors following the first dose of midodrine, increasing to
14 of 20 following the fourth dose. The rate of decline in
vasopressor requirements increased from 0.62 mcg/min per
hour to 2.20 mcg/min per hour (p = 0.012), meaning less
IV vasopressor was required. Mean arterial pressure
(MAP), heart rate (HR), and total body fluid balance
were not significantly different pre and post midodrine
administration, suggesting that changes in hemodynamic
status or fluid resuscitation were not responsible for the
change in the rate of decline in vasopressor requirements.
Cardenas et al. reported on the use of midodrine to wean
requirement of IV vasopressors in a medical ICU popula-
tion [8]. During a six month period, 50 patients who met
discharge criteria except for the use of low to moderate
dose of a single IV vasopressor were administered oral
midodrine (average initial and maximal doses 30.5 mg and
66.6 mg per day). Midodrine was continued on the ward
and reduced as tolerated by the admitting team. No adverse
effects were observed. In this study, 27 (54%) of the patients
were discharged from the hospital on midodrine (average
dose 17.8 mg per day). Another recent retrospective study
from a medical ICU included 275 patients over one year,
with a diagnosis of septic shock and required at least 24 h
of IV vasopressors, who were stable or on reducing doses
of IV vasopressors. The authors compared patients on IV
vasopressors only to those who received IV vasopressors
plus adjunctive midodrine (with a starting dose of 10 mg
TDS) and showed a reduction in the mean IV vasopressor
duration (2.9 days versus 3.8 days, p < 0.001) and reduced
ICU length of stay (7.5 versus 9.4 days, p = 0.017) in the IV
vasopressor plus midodrine group [9].
There are also a case report and two case series of the
use of midodrine to wean from or prevent the need for IV
vasopressors. O’Donnell reported on the use of midodrine
10 mg TDS to wean a patient from noradrenaline infusion
post C7 to T6 laminectomy for spinal cord compression
secondary to a leukemic deposit [10]. Sharma reported the
use of oral midodrine 10 mg TDS to wean IV dopamine
infusions in three patients with hypotension secondary to
myocardial stunning post percutaneous coronary inter-
vention [11]. Sharma also reported on the use of oral
midodrine for hypotension post carotid artery stenting.
Four patients with persistent hypotension post carotid ar-
tery stenting were successfully treated with midodrine
10 mg TDS, avoiding the requirement for ICU admission
(the preceding 11 cases required IV dopamine infusions in
ICU) [12].
The primary objective of this trial is to determine
whether addition of midodrine to standard care reduces the
time to discontinuation of IV vasopressor use. We will also
study whether hospital and ICU LOS are decreased, as well
as rates of ICU or high dependency unit (HDU) readmis-
sion, and rates of adverse events related to the use of mido-
drine (such as bradycardia and other hemodynamically
significant arrhythmias).
Methods
Study design and setting
This study will be an international, multicenter, random-
ized, double-blind, placebo-controlled intervention trial.
An outline of the study design is provided in Fig. 1.
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Study recruitment commenced in October 2012 at
Massachusetts General Hospital in Boston, United
States of America. We started enrolling patients at Sir
Charles Gairdner Hospital, Western Australia in 2016.
There is expectation of expansion to another academic
medical center. The trial is expected to be completed
by June 2017.
The IND application for midodrine (IND 113,330) was
approved by the United States FDA on Sep 12, 2011. A
notification to conduct the trial under the Clinical Trials
Notification (CTN) Scheme (Application ID CT-2016-
CTN-00226-1 v3) was acknowledged by the Australian
Government Therapeutic Goods Administration (TGA).
Ethics approval has been sought and obtained from the
ethics committees of participating hospitals (Partners
IRB Protocol #2011P002049, and Sir Charles Gairdner
Hospital HREC Protocol #2015-098).
Study population
A local investigator will screen ICU patients daily. Adult
patients admitted to the ICU or HDU who are hypotensive
and requiring IV vasopressors will be considered for the
study. A total of 120 patients will be recruited.
Inclusion and exclusion criteria
All adult patients who are hypotensive (systolic blood pres-
sure <90 mmHg) and require IV vasopressors for more
than 24 h are eligible for study inclusion. They should be
Fig. 1 Outline of study design
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otherwise resuscitated and have stable blood pressure on
single agent infusion of noradrenaline <8 mcg/min, or
phenylephrine <100 mcg/min, or metaraminol <60 mcg/
min). Table 1 outlines the exclusion criteria.
Intervention
A target blood pressure (systolic blood pressure (SBP) or
MAP) is determined by the treating physician at enrollment
of each patient. Eligible participants will be randomized to
receive midodrine 20 mg daily or placebo three times daily,
in addition to continuation of the IV vasopressor, until the
primary outcome (cessation of IV vasopressors) or an ad-
verse event occurs. The study drug and placebo will be de-
livered in the form of non-identifying capsules, containing
either the active ingredient midodrine, or lactose powder.
All patients will receive usual supportive care (intravenous
fluids, antibiotics etc.) as per the treating physicians and
standard practice. A flowchart of the study procedures is
shown in Fig. 2.
The study drug will be delivered in a double-blind
manner until:
1. Primary outcome is reached – cessation of IV
vasopressors; or
2. Patient is discharged from the ICU; or
3. Patient develops further hypotension – requiring
noradrenaline >8 mcg/min, phenylephrine
>100 mcg/min, or metaraminol >60 mcg/min; or
4. Adverse event occurs – subject develops signs and
symptoms of organ failure or hypoperfusion, adverse
events related to midodrine including serious allergic
reaction, or death.
Blinding and randomization
The principal investigator or research coordinator at each
participating site will enroll patients. All study personnel
will be blinded, except the investigational pharmacist, to
the treatment group of the subjects. Patients will be ran-
domly assigned in a 1:1 ratio to receive either midodrine
or placebo. Randomization will be performed with the use
of a computer-generated randomization list and will be
stratified by site. An independent statistician not respon-
sible for analyzing the data will create the allocation se-
quence. This list will be provided by the independent
statistician directly to the compounding pharmacy. Indi-
vidual patient’s drug bottles will be labeled with site-
specific randomization numbers, which will become the
patient’s study number. Study sites will dispense the study
drug bottles sequentially to patients in the order that they
are included in the study.
Outcomes
The primary outcome is time (hours) from initiation of
midodrine or placebo to discontinuation of IV vasopres-
sors. Secondary outcomes include time (hours) from
ICU admission to discharge readiness, ICU LOS (days),
hospital LOS (days), rates of readmission to ICU or
Table 1 Study exclusion criteria
Exclusion criteria Justification
Clinical evidence of inadequate tissue oxygenation For safety consideration, patients with ongoing shock
excluded.
Hypovolemic shock or hypotension due to adrenal
insufficiency (based on clinical suspicion or available
routine testing)
Treatable cause of hypotension.
Clinical evidence of liver failure Midodrine metabolism occurs predominantly in liver.
Pregnancy No safety data available.
Chronic renal failure (serum creatinine >2 mg/dL,
or 180umol/L)
Midodrine and its active metabolite are almost completely
excreted in urine. Drug accumulation may occur, and for
this trial dose adjustment is not possible.
Severe organic heart disease (ejection fraction less
than 30%)
Contraindicated due to higher risk of arrhythmias
Acute urinary retention Accumulation of drug may occur as usually almost
completed excreted in urine.
Pheochromocytoma (based on clinical suspicion) Contraindication.
Thyrotoxicosis (based on clinical suspicion) Contraindication.
Co-enrolment in another vasopressor clinical trial Confounding factor.
Midodrine as pre-admission medication Confounding factor.
Any known allergies to midodrine Contraindication.
Bradycardia (HR <50/min) Higher likelihood of symptomatic bradycardia.
No enteral route available Oral preparation.
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HDU, and rates of adverse events related to midodrine
administration. A cost consequence analysis will also be
performed by a medical economist based on the ICU
and hospital LOS.
Statistical analysis
The sample size estimation is informed by the previous
observational study by Levine et al. [7]. In this study, the
rates of vasopressor administration decreased by 38%
from −0.62 ± 1.40 mcg/min per hour to −2.20 ± 2.45 mcg/
min per hour after addition of midodrine. Based on a me-
dian time of 17 h from midodrine initiation to discontinu-
ation of IV vasopressors, the 38% reduction translates to
an estimated 6 h difference. 6 h is also thought to be a
meaningful time frame in terms of reduction in duration
of vasopressor treatment. Accordingly, we expect that a
sample size of 50 subjects per group will provide us with
>80% probability (power) to detect a difference of 6 h in
the primary outcome. Allowing for drop-out, our target
sample size is 120.
The study analysis will be by intention to treat. We will
analyze our data by using a Student’s t-test to determine
whether time from initiation of midodrine until discon-
tinuation of IV vasopressors, time from ICU/HDU admis-
sion to ICU/HDU discharge readiness, and ICU and
hospital LOS differs between groups. Using a Chi-Square
test, we will test whether rates of ICU/HDU readmission
and incidence of adverse events is different between treat-
ment groups. Time-dependent survival analysis will be
employed to assess relationships between addition of
midodrine/placebo and ICU/hospital LOS, with mortality
considered as the time-dependent covariate. A P value of
<0.05 will be considered statistically significant. All ana-
lyses will be conducted by a statistician blinded to inter-
vention group assignment.
Data collection
Baseline descriptive data collection will occur on day of
enrolment and includes age, gender, ethnicity, APACHE II
score, admission diagnosis, pre-existing co-morbidities
(diabetes, coronary artery disease, asthma, peripheral vas-
cular disease, renal failure, psychiatric disease, musculo-
skeletal disease, and others) obtained from the subject, the
subject’s family, and the subject’s medical chart. Baseline
laboratory data will be recorded (hemoglobin, white cell
count, alanine aminotransferase (ALT), international nor-
malized ratio (INR), bilirubin, urea, creatinine, troponin,
lactate). While in the study, hourly blood pressure, heart
rate, dose of intravenous vasopressor and daily SOFA
score will be recorded. The main outcome measure, time
in hours from initiation of midodrine until discontinu-
ation of IV vasopressors, will be recorded. To assess for
potential confounders, we will also record presence, and
time of removal, of epidural anesthesia, and any blood
transfusion. At the time of ICU discharge, the following
variables will be collected: time of ICU discharge readiness
and ICU LOS. After discharge, follow-up variables will be
rates of ICU readmission and hospital LOS and any other
complications. Data will be uploaded to a secure database
(REDCap) [13]. Data stored on REDCap are coded with-
out protected information. The center at Massachusetts
General Hospital owns the REDCap database, and is
responsible for all data entry and monitoring.
Fig. 2 Flowchart of study procedures
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Safety
The patient will be kept in the ICU for observation for 24 h
following cessation of study drug to reduce the likelihood
of hypotension or other side effects on discharge. If the
blood pressure goal is met for more than 24 h without IV
vasopressors, the study drug will be discontinued prior to
discharge to the ward. The accepting team will be informed
on discharge that the patient had received a study drug. In-
structions will be given to medical and nursing staff to con-
tact a physician investigator if the subject becomes
hypotensive in the 24 h after ICU discharge (defined as a
SBP <90 mmHg).
Adverse events
Adverse events will be recorded daily. Nursing charts
and documentation, as well as physicians’ notes will be
reviewed daily to identify potential adverse events. Ad-
verse events are defined as any unfavorable and unin-
tended signs, symptoms or diseases chronologically
associated with midodrine or placebo administration.
The relationship of any adverse event to the study drug
will be assessed by the investigator and qualified by
strength of association (not related, unlikely related, pos-
sibly related, probably related, or definitely related) and
severity of the event (mild, moderate or severe). All ad-
verse events will be summarized by the study staff and,
where appropriate, reported to the local human research
committee. Serious adverse events (SAE) are hyperten-
sion (increase in SBP 20% higher than the predefined
goal set by the primary team, or >160 mmHg), bradycar-
dia (decrease in heart rate 20% lower than the prede-
fined goal set by the primary team or <40 beats per
minute), hemodynamically significant tachyarrythmias
(resulting in drop in SBP >20 mmHg), or new organ fail-
ure (evidence of inadequate organ oxygenation, liver and
renal failure as per definitions in exclusion criteria).
Data and safety monitoring board
Data and safety monitoring board (DSMB) has been cre-
ated and comprises of physicians with relevant critical
care experience. The members are not involved in the
study and will be completely independent of any study-
related patient recruitment and data collection.
Ethics
Consent
As this is an international multicenter trial, the process of
informed consent may be different between sites, and will
be dependent on national and cultural standards. In-
formed consent will be obtained from the patient, or when
the patient is unable to consent, from the patient’s proxy.
A copy of the IRB approved informed consent form will
be given to the patient and/or healthcare proxy. All pa-
tients will be followed prospectively and given the
opportunity to consent to continue in the study following
resolution of their critical illness and capacity is regained.
Discussion
This article presents the protocol and data analysis plan
for the MIDAS trial; an international, multicenter, ran-
domized, double-blind, placebo-controlled clinical trial
evaluating the addition of midodrine to IV vasopressor
treatment in otherwise stable ICU patients.
Midodrine, an oral alpha-1 adrenergic agonist, was ap-
proved for the treatment of symptomatic orthostatic
hypotension under the United States FDA’s accelerated
approval regulations in 1996 [2]. In August 2010, the
FDA proposed to withdraw approval because of the lack
of post-approval studies that confirm the clinical benefit
of the drug [14]. It was the first time the agency had is-
sued such a notice. Subsequent to support for its use
from patients, doctors and professional organizations,
the FDA reversed its decision to withdraw approval [15],
but this decision was met with mixed response [16, 17].
Over recent years, there has been increasing interest in
using midodrine to help patients wean off or avoid IV va-
sopressors [6, 10–12]. The drug has a reasonable safety
profile, its main side effects being pilomotor reaction,
urinary retention, and supine hypertension. The use of an
oral vasopressor such as midodrine in addition to IV vaso-
pressors in otherwise resuscitated and stable ICU patients
has several reasons for attractiveness. Firstly, it helps to
avoid some of the potential complications of administer-
ing IV vasopressors, such as risks of central line insertion
and catheter-related bloodstream infections. Secondly,
they may help to shorten the duration of IV vasopressor
treatment, and hence reduce ICU length of stay and ICU-
acquired complications. This has significant cost implica-
tions for the patient and hospital.
We communicated directly with the United States FDA
and obtained IND approval to study the use of midodrine
in the ICU setting. In our pilot observational study [7], we
detected that midodrine treatment was associated with an
increase in the magnitude of decline of the IV vasopressor
rate. This pilot study offered promising data, but was lim-
ited in its small sample size (20 patients) and lack of a
control group. We designed the MIDAS trial as a prag-
matic clinical trial to study its use in routine patient care
conditions. We have designed the inclusion and exclusion
criteria so they can be applied to a broad clinical setting
across a wide range of patients. We hope to improve the
generalizability of our results by carrying out the study in
a multicentric design.
One limitation of this study is the fixed drug dosing. This
was selected to simplify the protocol and it was shown to
be safe during the pilot study. However, an individualized
dose titrated according to renal or hepatic function may
allow midodrine to be used in a wider range of patients. A
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second limitation is we do not have a standardized protocol
with regards to blood pressure targets for initiation, escal-
ation, or weaning of IV vasopressors. The different blood
pressure goals set by the primary care team may confound
the individual duration of vasopressor treatment. A third
limitation is that we are not studying the use of this drug
on the ward environment, which is another useful indica-
tion of midodrine in preventing ICU admission.
Conclusion
This manuscript provides a description of our study
protocol and analysis plans for the MIDAS international,
multicenter, randomized placebo- controlled clinical trial.
This trial is an opportunity to improve the efficiency of
our ICU beds and healthcare costs by facilitating early and
safe cessation of intravenous vasopressors in ICU patients.
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